<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6396361\results\search\country\results.xml">
  <result pre="G.2Abu�?RaddadLaith J.https://orcid.org/0000-0003-0790-0506lja2002@qatar-med.cornell.edu134[1], Infectious Disease Epidemiology GroupWeill Cornell Medicine�?Qatar, Cornell University," exact="Qatar" post="Foundation�?Education CityDohaQatar[2], Department of Communicable DiseasesHIV/Hepatitis/STIs Unit, World Health"/>
  <result pre="J. Abu�?Raddad, Ph.D. Infectious Disease Epidemiology Group Weill Cornell Medicine�?Qatar" exact="Qatar" post="Foundation�?Education City P.O. Box 24144 Doha, Qatar E�?mail: lja2002@qatar-med.cornell.edu"/>
  <result pre="Weill Cornell Medicine�?Qatar Qatar Foundation�?Education City P.O. Box 24144 Doha," exact="Qatar" post="E�?mail: lja2002@qatar-med.cornell.edu Tel.: +974 4492�?8321 epub: 2019-1-1collection: 2019-33310.1002/hep4.v3.3325339received: 2018-8-27accepted:"/>
  <result pre="population testing is not programmatically efficient in concentrated epidemics. Funding" exact="Qatar" post="National Research FundNPRP 9-040-3-008 fig-count: table-count: page-count: word-count: SEE"/>
  <result pre="ON PAGE 321 This work was made possible by the" exact="Qatar" post="National Research Fund (NPRP 9�?040�?3�?008 to L.J.A.). The statements"/>
  <result pre="Africa PWID people who inject drugs RR relative risk UAE" exact="United Arab Emirates" post="WHO World Health Organization Viral hepatitis is the seventh"/>
  <result pre="prevalence has reached high levels in populous countries, particularly in" exact="Egypt" post="and Pakistan, at 10.0%7, 8, 9, 10 and 4.8%,11,"/>
  <result pre="Pakistan,13 Palestine,35 Qatar,32 Saudi Arabia,32 Somalia,33 Sudan,33 Syria,35 Tunisia,31 the" exact="United Arab Emirates" post="(UAE),32 and Yemen.33 These reviews were informed by the"/>
  <result pre="Table 2. For PWID, the risk ranged between 25.0% in" exact="Lebanon" post="and 94.2% in Libya, with a median of 52.6%."/>
  <result pre="Conditions % (95% CI) Special Clinical Populations % (95% CI)" exact="Afghanistan" post="32.87 (25.17�?41.07) NA* 2.34 (1.29�?3.67) 0.74 (0.57�?0.93) NA* NA*"/>
  <result pre="Afghanistan 32.87 (25.17�?41.07) NA* 2.34 (1.29�?3.67) 0.74 (0.57�?0.93) NA* NA*" exact="Algeria" post="NA* 17.86 (11.25�?25.55) 4.96 (0.00�?17.31) 0.13 (0.03�?0.29) NA* 69.7†"/>
  <result pre="NA* 17.86 (11.25�?25.55) 4.96 (0.00�?17.31) 0.13 (0.03�?0.29) NA* 69.7† (65.05�?74.09)" exact="Bahrain" post="NA* 55.74 (26.35�?83.12) NA* NA* NA* 8.19 (0.00�?29.70) Djibouti"/>
  <result pre="(65.05�?74.09) Bahrain NA* 55.74 (26.35�?83.12) NA* NA* NA* 8.19 (0.00�?29.70)" exact="Djibouti" post="NA* NA* NA* 0.28 (0.21�?0.37) 0† (0.00�?0.06) NA* Egypt"/>
  <result pre="(0.00�?29.70) Djibouti NA* NA* NA* 0.28 (0.21�?0.37) 0† (0.00�?0.06) NA*" exact="Egypt" post="63.00† (52.76�?72.44) 55.44 (49.12�?61.67) 13.99 (10.09�?18.38) 11.83 (11.14�?12.53) 58.81"/>
  <result pre="24.80 (20.39�?29.48) 6.17 (3.44�?9.58) 0.29 (0.21�?0.37) 7.52 (4.34�?11.43) 2.65 (1.82�?3.61)" exact="Iraq" post="NA* 19.75 (15.11�?24.82) 1.26 (0.68�?1.98) 0.18 (0.13�?0.25) 6.97 (3.86�?10.84)"/>
  <result pre="19.75 (15.11�?24.82) 1.26 (0.68�?1.98) 0.18 (0.13�?0.25) 6.97 (3.86�?10.84) 2.77 (1.79�?3.92)" exact="Jordan" post="NA* 33.17 (25.27�?41.57) 0.66† (0.02�?3.61) 0.15 (0.07�?0.25) NA* 40.56†"/>
  <result pre="NA* 33.17 (25.27�?41.57) 0.66† (0.02�?3.61) 0.15 (0.07�?0.25) NA* 40.56† (32.43�?49.08)" exact="Kuwait" post="NA* 18.74 (5.73�?36.88) 5.34 (0.52�?14.33) 1.37 (0.05�?4.05) 5.88 (0.00�?23.25)"/>
  <result pre="18.74 (5.73�?36.88) 5.34 (0.52�?14.33) 1.37 (0.05�?4.05) 5.88 (0.00�?23.25) 60.60† (42.14�?77.09)" exact="Lebanon" post="25.03 (4.40�?54.51) 7.39 (4.16�?11.38) 2.16 (0.26�?5.36) 0.15 (0.06�?0.25) 19.57†"/>
  <result pre="7.39 (4.16�?11.38) 2.16 (0.26�?5.36) 0.15 (0.06�?0.25) 19.57† (12.03�?29.15) 0.00 (0.00�?0.76)" exact="Libya" post="94.20† (91.46�?96.72) 27.26 (18.85�?36.57) 5.38 (1.74�?10.73) 1.59 (1.44�?1.76) NA*"/>
  <result pre="(91.46�?96.72) 27.26 (18.85�?36.57) 5.38 (1.74�?10.73) 1.59 (1.44�?1.76) NA* 37.79 (24.84�?51.69)" exact="Mauritania" post="NA* NA* NA* 1.10† (0.31�?2.91) NA* NA* Morocco 52.97"/>
  <result pre="37.79 (24.84�?51.69) Mauritania NA* NA* NA* 1.10† (0.31�?2.91) NA* NA*" exact="Morocco" post="52.97 (33.11�?72.35) 38.34 (18.69�?60.15) 3.88 (2.32�?5.79) 0.65 (0.47�?0.86) 37.94"/>
  <result pre="38.34 (18.69�?60.15) 3.88 (2.32�?5.79) 0.65 (0.47�?0.86) 37.94 (3.70�?81.56) 9.02 (3.87�?15.87)" exact="Oman" post="48.05† (43.64�?52.47) 33.71 (20.83�?47.93) NA* 0.75 (0.60�?0.92) NA* 8.80"/>
  <result pre="48.05† (43.64�?52.47) 33.71 (20.83�?47.93) NA* 0.75 (0.60�?0.92) NA* 8.80 (0.92�?22.66)" exact="Pakistan" post="53.63 (36.21�?70.62) 32.84 (25.34�?40.78) 12.94 (10.85�?15.18) 6.15 (5.68�?6.65) 55.10"/>
  <result pre="Palestine 41.58 (36.24�?47.02) 10.34 (5.64�?16.17) NA* 0.24 (0.18�?0.30) NA* NA*" exact="Qatar" post="NA* 44.61† (35.90�?53.58) NA* 1.90 (1.09�?2.93) 33.08 (18.48�?49.47) 9.00†"/>
  <result pre="NA* 44.61† (35.90�?53.58) NA* 1.90 (1.09�?2.93) 33.08 (18.48�?49.47) 9.00† (4.19�?16.40)" exact="Saudi Arabia" post="58.67 (18.17�?93.10) 46.74 (43.12�?50.37) 8.95 (4.01�?15.49) 0.75 (0.68�?0.82) 27.23"/>
  <result pre="46.74 (43.12�?50.37) 8.95 (4.01�?15.49) 0.75 (0.68�?0.82) 27.23 (20.96�?33.97) 11.16 (7.86�?14.92)" exact="Somalia" post="NA* NA* 1.71 (0.10�?4.56) 1.07 (0.32�?2.15) 20.18 (4.52�?42.62) NA*"/>
  <result pre="Somalia NA* NA* 1.71 (0.10�?4.56) 1.07 (0.32�?2.15) 20.18 (4.52�?42.62) NA*" exact="Sudan" post="NA* 18.42 (8.42�?31.07) 0.70 (0.29�?1.24) 1.36 (0.63�?2.31) 7.32 (1.26�?17.0)"/>
  <result pre="43.53 (26.34�?61.56) 2.98 (1.77�?4.45) 0.41 (0.36�?0.47) 1.04† (0.13�?3.69) 48.00† (27.80�?68.69)" exact="Tunisia" post="85.61† (78.44�?91.11) 25.05 (20.24�?30.17) 6.30 (1.31�?14.38) 0.60 (0.44�?0.79) 22.42"/>
  <result pre="25.05 (20.24�?30.17) 6.30 (1.31�?14.38) 0.60 (0.44�?0.79) 22.42 (10.02�?37.78) 10.69 (0.28�?30.97)" exact="United Arab Emirates" post="NA* 24.00† (19.35�?30.09) 15.74 (3.58�?33.94) 2.02 (1.25�?2.96) NA* NA*"/>
  <result pre="Emirates NA* 24.00† (19.35�?30.09) 15.74 (3.58�?33.94) 2.02 (1.25�?2.96) NA* NA*" exact="Yemen" post="NA* 45.03 (33.10�?57.25) 1.63 (0.39�?3.61) 1.61 (1.12�?2.20) 25.09 (15.61�?35.90)"/>
  <result pre="HCV antibody prevalence in the general population being ≥3% (includes" exact="Egypt" post="and Pakistan). §Classification based on the pooled mean HCV"/>
  <result pre="general population being &amp;lt;3% (includes all MENA countries other than" exact="Egypt" post="and Pakistan). (C) John Wiley &amp;amp; Sons, Ltd, For"/>
  <result pre="high�?risk health care exposures, the risk ranged between 7.4% in" exact="Lebanon" post="and 55.7% in Bahrain, with a median of 30.1%."/>
  <result pre="intermediate risk, the risk was lower, ranging between 0.7% in" exact="Jordan" post="and 15.7% in the UAE, with a median of"/>
  <result pre="countries. For general populations, the risk ranged between 0.1% in" exact="Algeria" post="and 11.8% in Egypt, with a median of 0.8%."/>
  <result pre="populations with liver conditions, the risk ranged between 0% in" exact="Djibouti" post="and 58.8% in Egypt, with a median of 20.2%."/>
  <result pre="For special clinical populations, the risk ranged between 0% in" exact="Lebanon" post="and 69.7% in Algeria, with a median of 10.5%."/>
  <result pre="be tested to identify one case ranged from 1.4 in" exact="Libya" post="to 5.3 in Lebanon, with a median of 2.5."/>
  <result pre="Risk General Populations Populations With Liver Conditions Special Clinical Populations" exact="Afghanistan" post="4.1 (3.2�?5.3) NA* 57.0 (36.3�?103.4) 180.2 (143.4�?233.9) NA* NA*"/>
  <result pre="Afghanistan 4.1 (3.2�?5.3) NA* 57.0 (36.3�?103.4) 180.2 (143.4�?233.9) NA* NA*" exact="Algeria" post="NA* 7.5 (5.2�?11.9) 26.9 (7.7�? �?�?†) 1025.6 (459.8�?4444.4) NA*"/>
  <result pre="7.5 (5.2�?11.9) 26.9 (7.7�? �?�?†) 1025.6 (459.8�?4444.4) NA* 1.9 (1.8�?2.0)" exact="Bahrain" post="NA* 2.4 (1.6�?5.1) NA* NA* NA* 16.3 (4.5�? �?�?†)"/>
  <result pre="Bahrain NA* 2.4 (1.6�?5.1) NA* NA* NA* 16.3 (4.5�? �?�?†)" exact="Djibouti" post="NA* NA* NA* 476.2 (360.4�?634.9) NA† NA* Egypt 2.1"/>
  <result pre="(4.5�? �?�?†) Djibouti NA* NA* NA* 476.2 (360.4�?634.9) NA† NA*" exact="Egypt" post="2.1 (1.8�?2.5) 2.4 (2.2�?2.7) 9.5 (7.3�?13.2) 11.3 (10.6�?12.0) 2.3"/>
  <result pre="5.4 (4.5�?6.5) 21.6 (13.9�?38.8) 459.8 (360.4�?634.9) 17.7 (11.7�?30.7) 50.3 (36.9�?73.3)" exact="Iraq" post="NA* 6.8 (5.4�?8.8) 105.8 (67.3�?196.1) 740.7 (533.3�?1,025.6) 19.1 (12.3�?34.5)"/>
  <result pre="6.8 (5.4�?8.8) 105.8 (67.3�?196.1) 740.7 (533.3�?1,025.6) 19.1 (12.3�?34.5) 48.1 (34.0�?74.5)" exact="Jordan" post="NA* 4.0 (3.2�?5.3) 202 (36.9�?6,666.7) 888.9 (533.3�?1,904.8) NA* 3.3"/>
  <result pre="NA* 4.0 (3.2�?5.3) 202 (36.9�?6,666.7) 888.9 (533.3�?1,904.8) NA* 3.3 (2.7�?4.1)" exact="Kuwait" post="NA* 7.1 (3.6�?23.3) 25.0 (9.3�?256.4) 97.3 (32.9�?2,666.7) 22.7 (5.7�?"/>
  <result pre="(3.6�?23.3) 25.0 (9.3�?256.4) 97.3 (32.9�?2,666.7) 22.7 (5.7�? �?�?†) 2.2 (1.7�?3.2)" exact="Lebanon" post="5.3 (2.4�?30.3) 18.0 (11.7�?32.1) 61.7 (24.9�?512.8) 888.9 (533.3�?2,222.2) 6.8"/>
  <result pre="(2.4�?30.3) 18.0 (11.7�?32.1) 61.7 (24.9�?512.8) 888.9 (533.3�?2,222.2) 6.8 (4.6�?11.1) NA†" exact="Libya" post="1.4 (1.4�?1.5) 4.9 (3.6�?7.1) 24.8 (12.4�?76.6) 83.9 (75.8�?92.6) NA*"/>
  <result pre="(1.4�?1.5) 4.9 (3.6�?7.1) 24.8 (12.4�?76.6) 83.9 (75.8�?92.6) NA* 3.5 (2.6�?5.4)" exact="Mauritania" post="NA* NA* NA* 121.2 (45.8�?430.1) NA* NA* Morocco 2.5"/>
  <result pre="3.5 (2.6�?5.4) Mauritania NA* NA* NA* 121.2 (45.8�?430.1) NA* NA*" exact="Morocco" post="2.5 (1.8�?4.0) 3.5 (2.2�?7.1) 34.4 (23.0�?57.5) 205.1 (155.0�?283.7) 3.5"/>
  <result pre="3.5 (2.2�?7.1) 34.4 (23.0�?57.5) 205.1 (155.0�?283.7) 3.5 (1.6�?36.0) 14.8 (8.4�?34.5)" exact="Oman" post="2.8 (2.5�?3.1) 4.0 (2.8�?6.4) NA* 177.8 (144.9�?222.2) NA* 15.2"/>
  <result pre="2.8 (2.5�?3.1) 4.0 (2.8�?6.4) NA* 177.8 (144.9�?222.2) NA* 15.2 (5.9�?144.9)" exact="Pakistan" post="2.5 (1.9�?3.7) 4.1 (3.3�?5.3) 10.3 (8.8�?12.3) 21.7 (20.1�?23.5) 2.4"/>
  <result pre="Palestine 3.2 (2.8�?3.7) 12.9 (8.2�?23.6) NA* 555.6 (444.4�?740.7) NA* NA*" exact="Qatar" post="NA* 3.0 (2.5�?3.7) NA* 70.2 (45.5�?122.3) 4.0 (2.7�?7.2) 14.8"/>
  <result pre="NA* 3.0 (2.5�?3.7) NA* 70.2 (45.5�?122.3) 4.0 (2.7�?7.2) 14.8 (8.1�?31.8)" exact="Saudi Arabia" post="2.3 (1.4�?7.3) 2.9 (2.6�?3.1) 14.9 (8.6�?33.3) 177.8 (162.6�?196.1) 4.9"/>
  <result pre="2.9 (2.6�?3.1) 14.9 (8.6�?33.3) 177.8 (162.6�?196.1) 4.9 (3.9�?6.4) 11.9 (8.9�?17.0)" exact="Somalia" post="NA* NA* 78.0 (29.2�?1,333.3) 124.6 (62.0�?416.7) 6.6 (3.1�?29.5) NA*"/>
  <result pre="Somalia NA* NA* 78.0 (29.2�?1,333.3) 124.6 (62.0�?416.7) 6.6 (3.1�?29.5) NA*" exact="Sudan" post="NA* 7.2 (4.3�?15.8) 190.5 (107.5�?459.8) 98.0 (57.7�?211.6) 18.2 (7.8�?105.8)"/>
  <result pre="3.1 (2.2�?5.1) 44.7 (30.0�?75.3) 325.2 (283.7�?370.4) 128.2 (36.1�?1,025.6) 2.8 (1.9�?4.8)" exact="Tunisia" post="1.6 (1.5�?1.7) 5.3 (4.4�?6.6) 21.2 (9.3�?101.8) 222.2 (168.8�?303.0) 5.9"/>
  <result pre="5.3 (4.4�?6.6) 21.2 (9.3�?101.8) 222.2 (168.8�?303.0) 5.9 (3.5�?13.3) 12.5 (4.3�?476.2)" exact="United Arab Emirates" post="NA* 5.6 (4.4�?6.9) 8.5 (3.9�?37.2) 66.0 (45.0�?106.7) NA* NA*"/>
  <result pre="Emirates NA* 5.6 (4.4�?6.9) 8.5 (3.9�?37.2) 66.0 (45.0�?106.7) NA* NA*" exact="Yemen" post="NA* 3.0 (2.3�?4.0) 81.8 (36.9�?341.9) 82.8 (60.6�?119.0) 5.3 (3.7�?8.5)"/>
  <result pre="HCV antibody prevalence in the general population being ≥3% (includes" exact="Egypt" post="and Pakistan). §Classification based on the pooled mean HCV"/>
  <result pre="general population being &amp;lt;3% (includes all MENA countries other than" exact="Egypt" post="and Pakistan). (C) John Wiley &amp;amp; Sons, Ltd, For"/>
  <result pre="the number needed to be tested ranged from 2.4 in" exact="Bahrain" post="and Egypt to 18.0 in Lebanon, with a median"/>
  <result pre="needed to be tested ranged from 2.4 in Bahrain and" exact="Egypt" post="to 18.0 in Lebanon, with a median of 4.5."/>
  <result pre="needed to be tested was higher, ranging from 11.3 in" exact="Egypt" post="to 1,025.6 in Algeria, with a median of 177.8."/>
  <result pre="the number needed to be tested ranged from 2.3 in" exact="Egypt" post="to 128.2 in Syria, with a median of 6.3."/>
  <result pre="the number needed to be tested ranged from 1.9 in" exact="Algeria" post="to 50.3 in Iran, with a median of 12.5."/>
  <result pre="HCV using these data were 8.0% (95% CI, 6.1�?9.8) for" exact="Egypt" post="and 4.9% (95% CI, 4.7�?5.1) for Pakistan. The corresponding"/>
  <result pre="needed to be tested were 16.9 (95% CI, 13.6�?21.7) for" exact="Egypt" post="and 27.3 (95% CI, 26.3�?28.5) for Pakistan. These estimates"/>
  <result pre="in one country to another given epidemic history, say in" exact="Egypt" post="versus Pakistan.11, 13, 50 Inclusion of age, thus, is"/>
  <result pre="epidemic’s temporal evolution. Overall, data were most complete only for" exact="Egypt" post="and Pakistan, the two countries with generalized yet strikingly"/>
  <result pre="Population Egypt, El�?Zanaty and Associates Egypt, and ICF International ." exact="Egypt" post="Health Issues Survey 2015. Cairo, Egypt, and Rockville, MD:"/>
  <result pre="of Health and Population and ICF International; 2015. 8El�?ZanatyF, WayA." exact="Egypt" post="Demographic and Health Survey 2008. Cairo, Egypt: Ministry of"/>
  <result pre="for the Study of the Liver, April 22–26, 2015, Vienna," exact="Austria" post=". Gastroenterol Hepatol (N Y)2015;11(Suppl. 3):1�?23. 16ChenC. Gilead’s new"/>
  <result pre="for the Study of the Liver, April 13–17, 2016, Barcelona," exact="Spain" post=". Gastroenterol Hepatol (N Y)2016;12(Suppl. 2):1�?22. 18KimDD, HuttonDW, RaoufAA,"/>
  <result pre="Cost�?effectiveness model for hepatitis C screening and treatment: implications for" exact="Egypt" post="and other countries with high prevalence. Glob Public Health2015;10:296�?317.25469976"/>
  <result pre="Published June 21, 2017. Accessed March 8, 2018. 66El�?ZanatyF, WayA." exact="Egypt" post="Demographic and Health Survey 2008. Cairo, Egypt: Ministry of"/>
 </snippets>
</snippetsTree>
